Two Novartis scientists involved in Zolgensma data manipulation have been fired. The drugmaker said Brian and Allan Kaspar, the former chief scientific officer and VP at AveXis, respectively, have not been involved with the organization since May. Novartis also named Page Bouchard as SVP of research and chief scientific officer. Novartis bought AveXis last year. (STAT)
Sen. Bernie Sanders (I-VT) and Rep. Elijah Cummings (D-MD) have accused Mylan, Teva and Heritage of “coordinated obstruction” and “apparent efforts to stonewall” an investigation into generic drug prices. The lawmakers sent a letter to the three pharmaceutical companies requesting documents. (Reuters)
Canadian cannabis company Tilray has reported a wider-than-expected Q2 loss. Although sales increased year-over-year to $45.9 million, costs increased from investing in cultivation centers. The company plans to sell its first CBD products in the U.S. with Authentic Brands in the second of 2019. (CNBC)
TB Alliance’s drug-resistant tuberculosis treatment has received Food and Drug Administration approval. The drug, pretomanid, is to be used in combination with linezolid and bedaquiline as a six-month oral treatment regimen. Mylan will manufacture and sell the treatment. (Reuters)
Google searches after the El Paso shooting were higher than other recent mass shootings, after which public interest generally drops off in the following weeks. (Axios) Want to help keep the conversation moving? Be part of the solution by submitting to our #InspireTheEnd — Gun Violence initiative.